CC
ORIC icon

Casdin Capital’s Oric Pharmaceuticals ORIC Stock Holding History

Casdin Capital’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-601,515
Closed -$2.69M – 41
2022
Q2 		$2.69M Hold
601,515
– – 0.23% 36
2022
Q1 		$3.21M Hold
601,515
– – 0.14% 45
2021
Q4 		$8.84M Hold
601,515
– – 0.25% 47
2021
Q3 		$12.6M Hold
601,515
– – 0.31% 43
2021
Q2 		$10.6M Hold
601,515
– – 0.27% 42
2021
Q1 		$14.7M Hold
601,515
– – 0.44% 36
2020
Q4 		$20.4M Buy
601,515
+350,000
+139% +$10M 0.6% 35
2020
Q3 		$6.29M Hold
251,515
– – 0.28% 42
2020
Q2 		$8.48M Buy
+251,515
New +$8.03M 0.5% 37

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Casdin Capital's ORIC Position: Q3 2022 in Review

Casdin Capital sold out of Oric Pharmaceuticals (ORIC) in Q3 2022, closing a stake of 601,515 shares — an estimated $2.69M sold.

Casdin Capital first reported a position in ORIC in Q2 2020 and held it in 9 quarters. The position peaked at $20.4M in Q4 2020. 76 funds tracked by Wall St. Rank hold ORIC as of Q3 2022.

  • Casdin Capital reported no remaining Oric Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Casdin Capital sold 601,515 Oric Pharmaceuticals shares in Q3 2022, an estimated $2.69M.
  • Casdin Capital first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 9 quarters.
  • Casdin Capital's Oric Pharmaceuticals position peaked at $20.4M in Q4 2020.
  • 76 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2022.

Based on Casdin Capital's 13F filing for Q3 2022, filed 14 Nov 2022.